JP2008504363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504363A5 JP2008504363A5 JP2007518739A JP2007518739A JP2008504363A5 JP 2008504363 A5 JP2008504363 A5 JP 2008504363A5 JP 2007518739 A JP2007518739 A JP 2007518739A JP 2007518739 A JP2007518739 A JP 2007518739A JP 2008504363 A5 JP2008504363 A5 JP 2008504363A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- alkyl
- dioxo
- benzamide
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- -1 hydroxy, amino Chemical group 0.000 claims 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000006573 (C1-C10) heteroaryl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 4
- 229960001940 sulfasalazine Drugs 0.000 claims 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 3
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- LMVZQBQXTHCTDI-UHFFFAOYSA-N 2-chloro-5-[4-(2,3-dihydroxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[(1-hydroxycyclohexyl)methyl]benzamide Chemical compound O=C1N(CC(O)CO)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCC2)=C1 LMVZQBQXTHCTDI-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 150000002829 nitrogen Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- KJPZROKEPKPKNY-UHFFFAOYSA-N 2-chloro-5-[3,5-dioxo-4-(3,3,3-trifluoro-2-hydroxypropyl)-1,2,4-triazin-2-yl]-n-[(1-hydroxycycloheptyl)methyl]benzamide Chemical compound O=C1N(CC(O)C(F)(F)F)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 KJPZROKEPKPKNY-UHFFFAOYSA-N 0.000 claims 1
- JMVYKXHUTCCANK-UHFFFAOYSA-N 2-chloro-5-[4-(2,3-dihydroxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[(1-hydroxycycloheptyl)methyl]benzamide Chemical compound O=C1N(CC(O)CO)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 JMVYKXHUTCCANK-UHFFFAOYSA-N 0.000 claims 1
- JBSOMXMDEHIYEI-UHFFFAOYSA-N 2-chloro-5-[4-(2-cyanoethyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[(1-hydroxycycloheptyl)methyl]benzamide Chemical compound C=1C(N2C(N(CCC#N)C(=O)C=N2)=O)=CC=C(Cl)C=1C(=O)NCC1(O)CCCCCC1 JBSOMXMDEHIYEI-UHFFFAOYSA-N 0.000 claims 1
- SKHOFKQIJDWTCL-UHFFFAOYSA-N 2-chloro-5-[4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-(2-hydroxy-2-phenylethyl)benzamide Chemical compound O=C1N(CC(O)COC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC(O)C=2C=CC=CC=2)=C1 SKHOFKQIJDWTCL-UHFFFAOYSA-N 0.000 claims 1
- GELUSLDHFNHTJQ-UHFFFAOYSA-N 2-chloro-5-[4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[[1-(hydroxymethyl)cycloheptyl]methyl]benzamide Chemical compound O=C1N(CC(O)COC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(CO)CCCCCC2)=C1 GELUSLDHFNHTJQ-UHFFFAOYSA-N 0.000 claims 1
- IUPMKDQZZPUSLS-UHFFFAOYSA-N 2-chloro-5-[4-(cyanomethyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[(1-hydroxycycloheptyl)methyl]benzamide Chemical compound C=1C(N2C(N(CC#N)C(=O)C=N2)=O)=CC=C(Cl)C=1C(=O)NCC1(O)CCCCCC1 IUPMKDQZZPUSLS-UHFFFAOYSA-N 0.000 claims 1
- CMDPHTPJKKJNDM-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-hydroxy-2-methylpropyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CC(C)(O)C)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 CMDPHTPJKKJNDM-UHFFFAOYSA-N 0.000 claims 1
- OAEZUGNBLUMOLY-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-hydroxy-2-phenylethyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound C=1C=CC=CC=1C(O)CN(C1=O)C(=O)C=NN1C(C=1)=CC=C(Cl)C=1C(=O)NCC1(O)CCCCCC1 OAEZUGNBLUMOLY-UHFFFAOYSA-N 0.000 claims 1
- FUCKCIVGBCBZNP-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CC(O)COC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 FUCKCIVGBCBZNP-UHFFFAOYSA-N 0.000 claims 1
- KMQUFVMVCXCGKB-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-hydroxyethyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CCO)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 KMQUFVMVCXCGKB-UHFFFAOYSA-N 0.000 claims 1
- RBAADOGLQCDEJX-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-methoxyethyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CCOC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 RBAADOGLQCDEJX-UHFFFAOYSA-N 0.000 claims 1
- UTVQECIXWCMQOC-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycyclohexyl)methyl]-5-[4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CC(O)COC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCC2)=C1 UTVQECIXWCMQOC-UHFFFAOYSA-N 0.000 claims 1
- NAVAMNWMBLWSNC-UHFFFAOYSA-N 2-chloro-n-[(1-hydroxycyclooctyl)methyl]-5-[4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide Chemical compound O=C1N(CC(O)COC)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCCC2)=C1 NAVAMNWMBLWSNC-UHFFFAOYSA-N 0.000 claims 1
- RGFRMICGIFODJR-UHFFFAOYSA-N 5-[4-(2,3-dihydroxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-n-[(1-hydroxycycloheptyl)methyl]-2-methylbenzamide Chemical compound CC1=CC=C(N2C(N(CC(O)CO)C(=O)C=N2)=O)C=C1C(=O)NCC1(O)CCCCCC1 RGFRMICGIFODJR-UHFFFAOYSA-N 0.000 claims 1
- BSTQMIPJWUKIBV-UHFFFAOYSA-N 5-[4-(3-amino-2-hydroxypropyl)-3,5-dioxo-1,2,4-triazin-2-yl]-2-chloro-n-[(1-hydroxycycloheptyl)methyl]benzamide Chemical compound O=C1N(CC(O)CN)C(=O)C=NN1C1=CC=C(Cl)C(C(=O)NCC2(O)CCCCCC2)=C1 BSTQMIPJWUKIBV-UHFFFAOYSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- MDTBAOKMFWFWIA-UHFFFAOYSA-N n-[(1-hydroxycycloheptyl)methyl]-5-[4-(2-hydroxyethyl)-3,5-dioxo-1,2,4-triazin-2-yl]-2-methylbenzamide Chemical compound CC1=CC=C(N2C(N(CCO)C(=O)C=N2)=O)C=C1C(=O)NCC1(O)CCCCCC1 MDTBAOKMFWFWIA-UHFFFAOYSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58394304P | 2004-06-29 | 2004-06-29 | |
| PCT/IB2005/002195 WO2006003517A1 (en) | 2004-06-29 | 2005-06-16 | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504363A JP2008504363A (ja) | 2008-02-14 |
| JP2008504363A5 true JP2008504363A5 (https=) | 2008-03-27 |
Family
ID=34979502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518739A Withdrawn JP2008504363A (ja) | 2004-06-29 | 2005-06-16 | Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060018904A1 (https=) |
| EP (1) | EP1763353A1 (https=) |
| JP (1) | JP2008504363A (https=) |
| BR (1) | BRPI0512915A (https=) |
| CA (1) | CA2572119A1 (https=) |
| MX (1) | MXPA06014023A (https=) |
| WO (1) | WO2006003517A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| MXPA05012086A (es) | 2003-05-12 | 2006-02-22 | Pfizer Prod Inc | Inhibidores de benzamida del receptor p2x7. |
| EP2046383B1 (en) * | 2006-07-04 | 2014-11-19 | Genmab A/S | Cd20 binding molecules for the treatment of copd |
| GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| HUE032563T2 (en) | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| EP2170848B1 (en) | 2007-06-27 | 2014-10-22 | AstraZeneca AB | Pyrazinone derivatives and their use in the treatment of lung diseases |
| WO2009019503A2 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | P2x7 antagonists for use in the treatment of mood disorders |
| JP2009092508A (ja) * | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
| GB0724258D0 (en) * | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
| CA2717166A1 (en) * | 2008-03-03 | 2009-09-19 | Converge Biotech Inc. | Methods of modulating t cell-dependent immune responses |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| CA2744400C (en) * | 2008-11-25 | 2019-01-15 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| JP2013521002A (ja) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 誘導樹状細胞組成物及びその使用 |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | Ｈ 朗德貝克公司 | 苯甲醯胺類 |
| WO2015099107A1 (ja) | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | 含窒素６員環誘導体およびそれらを含有する医薬組成物 |
| WO2016022465A1 (en) * | 2014-08-04 | 2016-02-11 | Drexel University | Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same |
| EP3957627B1 (en) | 2015-04-24 | 2024-06-19 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| KR102528627B1 (ko) | 2016-10-17 | 2023-05-03 | 시오노기 앤드 컴파니, 리미티드 | 2환성 함질소 헤테로환 유도체 및 그를 함유하는 의약 조성물 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318731A (en) * | 1979-08-25 | 1982-03-09 | Nihon Nohyaku Co., Ltd. | Δ2 -1,2,4-triazolin-5-one derivatives and herbicidal usage thereof |
| AU542544B2 (en) * | 1980-03-12 | 1985-02-28 | Nippon Kayaku Kabushiki Kaisha | Tetrahydrophthalimide derivatives |
| US4766233A (en) * | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
| WO1986000072A1 (en) * | 1984-06-12 | 1986-01-03 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2h,4h)-diones and sulfur analogs thereof |
| US4806145A (en) * | 1984-10-31 | 1989-02-21 | Fmc Corporation | Herbicidal aryl triazolinones |
| JPS6299368A (ja) * | 1985-10-26 | 1987-05-08 | Nippon Nohyaku Co Ltd | Δ↑２−１，２，４−トリアゾリン−５−オン誘導体及びその製法並びにその用途 |
| WO1989002891A1 (fr) * | 1987-09-23 | 1989-04-06 | F. Hoffmann-La Roche & Co. Aktiengesellschaft | Composes heterocycliques |
| US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
| US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
| JP3290657B2 (ja) * | 1991-05-01 | 2002-06-10 | メルク エンド カムパニー インコーポレーテッド | アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体 |
| SE9103397D0 (sv) * | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
| US5686061A (en) * | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
| US6001862A (en) * | 1995-06-02 | 1999-12-14 | Kyorin Pharameuticals Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same |
| US6147101A (en) * | 1995-06-02 | 2000-11-14 | Kyorin Pharmaceutical Co., Ltd. | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same |
| JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| JP3906935B2 (ja) * | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| US5939418A (en) * | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
| PT889877E (pt) * | 1996-03-29 | 2002-02-28 | Searle & Co | Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3 |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| DE19701287A1 (de) * | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben |
| US6265409B1 (en) * | 1997-03-25 | 2001-07-24 | Astrazeneca Ab | Pyridine derivatives and pharmaceutical compositions containing them |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| SE9704272D0 (sv) * | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JPH11318492A (ja) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | 蛍光発生性基質を含有する組成物 |
| US6320078B1 (en) * | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
| FR2783519B1 (fr) * | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| DE19851184A1 (de) * | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| CN1147483C (zh) * | 1999-04-09 | 2004-04-28 | 阿斯特拉曾尼卡有限公司 | 金刚烷衍生物 |
| SE9901875D0 (sv) * | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| DE10005284A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen |
| HU229494B1 (en) * | 2000-05-04 | 2014-01-28 | Basf Ag | Uracil substituted phenyl sulfamoyl carboxamides |
| WO2002046186A1 (en) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| MXPA05012086A (es) * | 2003-05-12 | 2006-02-22 | Pfizer Prod Inc | Inhibidores de benzamida del receptor p2x7. |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
-
2005
- 2005-06-16 BR BRPI0512915-0A patent/BRPI0512915A/pt not_active Application Discontinuation
- 2005-06-16 MX MXPA06014023A patent/MXPA06014023A/es unknown
- 2005-06-16 CA CA002572119A patent/CA2572119A1/en not_active Abandoned
- 2005-06-16 EP EP05759633A patent/EP1763353A1/en not_active Withdrawn
- 2005-06-16 WO PCT/IB2005/002195 patent/WO2006003517A1/en not_active Ceased
- 2005-06-16 JP JP2007518739A patent/JP2008504363A/ja not_active Withdrawn
- 2005-06-28 US US11/168,602 patent/US20060018904A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504363A5 (https=) | ||
| JP2006513206A5 (https=) | ||
| CA2512193A1 (en) | 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases | |
| JP2005501120A5 (https=) | ||
| JP2010538076A5 (https=) | ||
| JP2010532387A5 (https=) | ||
| JP2016520618A5 (https=) | ||
| JP2013543896A5 (https=) | ||
| JP2003528859A5 (https=) | ||
| JP2006514626A5 (https=) | ||
| JP2009512659A5 (https=) | ||
| JP2005506334A5 (https=) | ||
| JP2009503107A5 (https=) | ||
| JP2006517939A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| JP2008504363A (ja) | Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法 | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2019502708A5 (https=) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2006515339A5 (https=) | ||
| JP2007516205A5 (https=) | ||
| JP2007529499A5 (https=) |